Previous 10 | Next 10 |
-- New findings presented during the Academy of Managed Care Pharmacy Nexus 2020 Virtual Meeting showed most patients had at least some improvement in one or more disease parameters for up to one year following TEPEZZA treatment for TED, and are supported by recently announced long-te...
KRYSTEXXA, combined with the immunomodulator methotrexate, has been able to improve the response rate in patients with refractory gout. Horizon to present results of study using both KRYSTEXXA and mycophenolate mofetil (immunomodulator) as another potential combination to treat refrac...
The stock price performance of HZNP has been one of the best in the biotech universe year to date. The launch of Tepezza has been probably the best in the rare disease space ever. The stock price might be negatively impacted by the second wave of lockdown restrictions in the U.S. ...
Genmab has continued to make great progress since my initial coverage a year ago. The company's portfolio of current and future therapeutics in association with world-class partners bodes well for continued breakthroughs in the fight against cancer. However, one issue of concern m...
-- Presentations will add to the growing body of evidence on the use of KRYSTEXXA with an immunomodulator to impact patient outcomes -- -- Oral presentation on Nov. 7 at 5:20 p.m. ET discussing data from RECIPE, the randomized controlled trial studying the concomitant use of K...
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its third-quarter 2020 financial results will be released on Monday, Nov. 2, 2020. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operatin...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named one of “ San Francisco Bay Area's Best and Brightest Companies to Work For .” This is the first year that Horizon has been named to the list since opening the company’s South San Fran...
Horizon's competitor Selecta announced that SEL-212 failed to beat Krystexxa in a head-to-head trial in refractory gout patients. SEL-212 achieved numerically higher response rates against Krystexxa monotherapy, but Krystexxa in combination with methotrexate will likely achieve signif...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that TEPEZZA ® (teprotumumab-trbw) was selected as a 2020 R&D World R&D 100 Award recipient in the Process/Prototyping category. TEPEZZA is the first and only medicine approved by the U.S. Food and Drug Adm...
-- Horizon was nominated for this award for helping facilitate global adoptions of children with rare diseases through Gift of Adoption partnership -- Horizon Therapeutics plc (Nasdaq: HZNP) was named as a 2020 Angels in Adoption ® Honoree for the company’s o...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Horizon Therapeutics Public Limited Company Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...